Norris Medicines
Norris Medicines (NORRIS) share price was ₹14.62 at the 28 Oct 2026 close; market capitalisation ₹14.62 Cr; sector Commercial Services. The share price fell 5.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 37.0% year on year to ₹0.92 Cr and net profit was −₹0.40 Cr, against −₹0.31 Cr a year earlier (compared with Jun 2025). Promoters held 34.01% of Norris Medicines in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 49/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapCommercial ServicesServicesPrice-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Services › Commercial Services › Trading & Distributors
| ₹350.30 | 16.10 | 27,386 Cr | 2.70 | 1.68% | 12.32% | 19.00% | 1,28,312 Cr | 1,504 Cr | |
| ₹51.54 | 17.30 | 7,731 Cr | 3.64 | 0.00% | 18.27% | 29.75% | 908 Cr | 447 Cr | |
| ₹566.30 | 17.01 | 3,987 Cr | 4.41 | 2.82% | 24.16% | 31.29% | 478 Cr | 234 Cr | |
| ₹1,171.10 | 23.88 | 1,759 Cr | 4.39 | 0.05% | 18.15% | 26.34% | 2,794 Cr | 74 Cr | |
| — | — | 1,104 Cr | 12.25 | 0.00% | -0.05% | 0.02% | 40 Cr | -0 Cr | |
| — | — | 810 Cr | 59.90 | 0.00% | 53.72% | 74.36% | 12 Cr | -2 Cr | |
| Norris Medicines (this company) | — | — | 15 Cr | — | 0.00% | 1.85% | 6.52% | 8 Cr | -0 Cr |
| Median 7 companies | ₹458.30 | 17.16 | 1,759 Cr | 4.40 | 0.00% | 18.15% | 26.34% | 478 Cr | 74 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 86/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Debtor days have improved from 69.8 to 52.5 days.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -7.87% over past five years.
- Promoter holding is low: 34.0%
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin -30.43% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.95 | 2.56 | 0.65 | 1.49 | 0.72 | 1.27 | 1.11 | 2.72 | 1.46 | 2 | 3.27 | 1.41 | 0.92 |
| Expenses | 1.33 | 2.8 | 0.69 | 1.01 | 0.88 | 1.42 | 1.14 | 2.65 | 1.56 | 2.49 | 2.32 | 1.11 | 1.2 |
| Operating Profit | -0.38 | -0.24 | -0.04 | 0.48 | -0.16 | -0.15 | -0.03 | 0.07 | -0.1 | -0.49 | 0.95 | 0.3 | -0.28 |
| OPM % | -40% | -9.38% | -6.15% | 32.21% | -22.22% | -11.81% | -2.7% | 2.57% | -6.85% | -24.5% | 29.05% | 21.28% | -30.43% |
| Other Income | 0 | 0 | 0 | 0.03 | 0.01 | 0 | 0 | 0.05 | 0.02 | 0 | 0 | 0.02 | 0 |
| Interest | 0.09 | 0.09 | 0.09 | 0.11 | 0.08 | 0.08 | 0.12 | 0.15 | 0.11 | 0.11 | 0.13 | 0.15 | 0 |
| Depreciation | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | 0.13 | 0.13 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| PBT | -0.61 | -0.47 | -0.27 | 0.26 | -0.36 | -0.36 | -0.28 | -0.17 | -0.31 | -0.72 | 0.7 | 0.05 | -0.39 |
| Tax % | 0% | 0% | 0% | 34.62% | 0% | 0% | 0% | 35.29% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.61 | -0.48 | -0.27 | 0.17 | -0.37 | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
| EPS (₹) | -0.61 | -0.48 | -0.27 | 0.17 | -0.37 | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 | 7.6 |
| Expenses | 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10 | 14 | 9.52 | 7.43 | 5.81 | 6.08 | 7.47 | 7.12 |
| Operating Profit | 1.71 | 0.83 | 0 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.66 | 0.48 |
| OPM % | 9.15% | 4.4% | 0% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 8.12% | 6.32% |
| Other Income | 0.15 | 0.3 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 |
| Interest | 0.54 | 0.67 | 0.6 | 0.7 | 0.73 | 0.88 | 1.63 | 1.48 | 1.5 | 0.37 | 0.44 | 0.5 | 0.39 |
| Depreciation | 1.31 | 0.6 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.49 | 0.47 |
| PBT | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4 | -2.19 | -1.19 | -1.1 | -1.18 | -0.28 | -0.36 |
| Tax % | 10500% | -128.57% | -35.29% | -21% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | 5.08% | 0% | — |
| Net Profit | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| EPS (₹) | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves | -4.63 | -4.6 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 | -25.07 |
| Borrowings | 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.4 | 21.52 | 21.58 | 21.53 |
| Other Liabilities | 4.69 | 5.06 | 9.9 | 10.92 | 8.76 | 5.1 | 11.69 | 3.8 | 4.72 | 6.29 | 7.09 | 6.5 |
| Total Liabilities | 18.15 | 17.9 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
| Fixed Assets | 8.61 | 8.34 | 9.97 | 9.32 | 8.9 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | 4.79 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.3 | 12.1 | 7.11 | 7.2 | 8.38 | 8.53 | 8.09 |
| Total Assets | 18.15 | 17.9 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -1.43 | 1.35 | -0.96 | 0.8 | -1.92 | -2.88 | 1.11 | -1.01 | 1.2 | 0.17 | 0.51 | 0.59 |
| Investing | -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | 0 | -0.06 | -0.09 | -0.02 | 0.05 | 0 | -0.09 |
| Financing | 0.1 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.1 | -1.18 | -0.2 | -0.5 | -0.52 |
| Net Cash Flow | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0 | 0 | 0.02 | 0 | -0.02 |
| Free Cash Flow | -2.3 | 1.03 | -3.24 | 0.74 | -2.21 | -2.96 | 1.02 | -1.07 | 1.17 | 0.26 | 0.49 | 0.58 |
| CFO/OP | -84 | 163 | — | -42 | 315 | 133 | -63 | 1,262 | 129 | -100 | -196 | 89 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73.66 | 53.61 | 84.2 | 66.44 | 67.57 | 128 | 53.33 | 42.15 | 48.03 | 68.6 | 88.43 | 52.53 |
| Inventory Days | 100 | 134 | 130 | 239 | 135 | 324 | 213 | 157 | 348 | 594 | 437 | 338 |
| Days Payable | 112 | 99.3 | 125 | 252 | 140 | 233 | 219 | 86.53 | 150 | 244 | 321 | 222 |
| Cash Conversion Cycle | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 219 | 47.49 | 113 | 246 | 419 | 205 | 168 |
| Working Capital Days | 27.75 | 34.84 | -16.06 | -91.18 | -32.55 | -30.73 | -104 | -97.82 | -122 | -203 | -241 | -167 |
| ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.2% | -8.43% | -10.13% | 3.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Norris Medicines insights
58 extracted metrics + investor summaries across FY00–FY27.
Documents
Frequently Asked Questions about Norris Medicines
What does Norris Medicines Ltd do?
Where is Norris Medicines Ltd (NORRIS) listed?
Which sector does Norris Medicines Ltd belong to?
What is the market capitalisation of Norris Medicines Ltd?
What is the 52-week high and low of Norris Medicines Ltd?
What is the Return on Equity (ROE) of Norris Medicines Ltd?
Company Information
Incorporated in 1990, Norris Medicines Ltd is a manufacturer of Injections and Medicinal formulations[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524414.md for Norris Medicines Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.